Hangzhou AGS Medtech Co (SHSE:688581) ROCE % : 10.97% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Hangzhou AGS Medtech Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Hangzhou AGS Medtech Co's annualized ROCE % for the quarter that ended in Mar. 2024 was 10.97%.

Hangzhou AGS Medtech Co ROCE % Historical Data

The historical data trend for Hangzhou AGS Medtech Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou AGS Medtech Co ROCE % Chart

Hangzhou AGS Medtech Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

42.42

26.59

109.32

45.75

19.42

Hangzhou AGS Medtech Co Quarterly Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial											39.11	16.41	14.11	16.14	10.97

Hangzhou AGS Medtech Co ROCE % Calculation

Hangzhou AGS Medtech Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	251.718	/	( ( (473.131 - 91.027)	+	(2331.074 - 120.735) )	/ 2 )
	=	251.718	/	( (382.104	+	2210.339)	/ 2 )
	=	251.718	/	1296.2215
	=	19.42 %

Hangzhou AGS Medtech Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	244.308	/	( ( (2331.074 - 120.735)	+	(2329.419 - 85.213) )	/ 2 )
	=	244.308	/	( ( 2210.339	+	2244.206 )	/ 2 )
	=	244.308	/	2227.2725
	=	10.97 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Hangzhou AGS Medtech Co (SHSE:688581) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Hangzhou AGS Medtech Co ROCE % Related Terms

Thank you for viewing the detailed overview of Hangzhou AGS Medtech Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hangzhou AGS Medtech Co (SHSE:688581) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hangzhou AGS Medtech Co Ltd (SHSE:688581) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 6 Kangxin Road, Building 597, Building 5, Yuhang District, Zhejiang Province, Hangzhou, CHN, 311106

Website

http://www.bioags.com

Hangzhou AGS Medtech Co Ltd is engaged in Research & Development, production, and sales of endoscopic minimally invasive diagnosis and treatment devices. The company upholds the core values of create, insist, share, and providing patients and clinicians with safer and more efficient minimally invasive endoscopic devices, helping patients reduce pain and medical costs.

Hangzhou AGS Medtech Co (SHSE:688581) Headlines

No Headlines